David Fishlock | Nov 15, 1987 | 2 min read
LONDON—Squibb Corporation, the U.S. pharmaceutical company, plans to spend $32 million over the next seven years at Oxford University on basic neuroscience research. The agreement is one of the biggest between industry and academia since Hoechst announced its $50 million, 10-year investment in molecular biology at the Massachusetts General Hospital in 1982. Squibb is the first company to respond with cash to a workshop, organized jointly by the university and Britain’s Medical R